Science Pool

Learn more about the human SLC uptake transporter inhibition assay including:

• Background information
• Assay details and protocol summary
• Data generated in the SLC transporter inhibition assay

Learn more about reaction phenotyping including:

• Background information
• Assay details and protocol summary
• Data generated in the reaction phenotyping assay

Learn more about the P-gp inhibition assay including:

• background information on P-gp inhibition
• assay details and protocol summary for the P-gp inhibition assay
• data generated in the P-gp inhibition assay

Learn more about the human MRP transporter substrate identification assay including:

• Background information
• Assay details and protocol summary
• Data generated in the MRP transporter substrate identification assay

Download this fact sheet to learn more about the MDCK-MDR1 permeability assay including:

• Background information
• Assay details and protocol summary
• Data generated in the MDCK-MDR1 permeability assay

Learn more about the low clearance Hurel co-culture assay including:

• Background information
• Assay details and protocol summary
• Data generated in the low clearance Hurel co-culture assay

Learn more about the human SLC transporter substrate identification assay including:

• Background information
• Assay details and protocol summary
• Data generated in the SLC transporter substrate identification assay

Learn more about the P-gp substrate identification assay including:

• Background information
• Assay details and protocol summary
• Data generated in the P-gp substrate identification assay

Drug-drug interaction (DDI) studies are an important part of the regulatory drug development process. The US FDA, EMA and Japanese PMDA have issued guidance on the conduct of these DDI studies, however, a harmonised guidance is currently under review (ICH M12) and is expected to be adopted in April 2024. The risk of DDI can be assessed in vitro and data analysed using models of varying complexity.  As identifying potential safety issues is the main purpose of these studies, many of the models have been developed to over-estimate the risk of DDI .This, however, needs to be balanced with the risk of false positives and the potential of unnecessary clinical DDI studies which are expensive and time consuming to perform. It is essential, therefore, to choose the most accurate model when analysing data from in vitro DDI studies.   

In this poster, we focus on:

• an evaluation of the various models for predicting clinical CYP3A4 induction risk from in vitro data
• a comparison of basic R₃ values (with and without a scaling factor) with correlation methods (relative induction score (RIS) and I_max/EC₅₀ values)

Read our poster to learn more about our research!

LEARN MORE

LC-MS/MS produces highly sensitive, specific and reproducible data, however, throughput can be a limitation and this can lead to a bottleneck in sample analysis from pharmacokinetic (PK) studies.

In this poster, we focus on:

• the development of ultra-fast separation chromatography to improve efficiency of sample analysis in small molecule PK studies
• a comparison of the rapid separation method with conventional column technology for the analysis of plasma and blood samples from a PK study

Read our poster to learn more about our research!

LEARN MORE